Group >	25:1		50:1	
Ex. No v	Control	Peptides from Casein	Control	Peptides from Casein
1	16.10	43.80	27.50	62.80
2	25.70	45.40	18.20	43.40
3	0.00	3.10	0.00	35.00
4	-	-	9.00	35.00
Average	**13.93**	**30.77**	**13.68**	**44.05**
SD	**12.99**	**23.97**	**11.84**	**13.11**



Fig. 1

Dose>	0	5	10	25	50	100	250	500
1:50	3.9	5.4	11.3	10.9	9.1	8.3	12.5	15.5
1:100	4.6	5.1	12.4	12.8	11.9	10.8	12.1	14.9



Fig. 2a

Patient	Type	0	10	25	100	250	500
1	Normal	13	15	15	12	13	15
2	NHL	10.1	13.8	14.3	-	15.8	13.7
3	NHL	3.5	10.4	8.4	10.8	-	-
4	Br.Ca	4.2	2.7	7.1	7.7	5.9	10.1
5	-	12.2	18.1	19.1	14.3	13.4	15.8
6	-	17	15	15	15	13	9

Fig. 2b

Patient	Control	Peptides from Casein
1	0.60	0.20
2	0.60	1.90
3	0.10	0.90
4	0.40	3.30
5	1.50	3.70
Mean	0.64	2.00
SD	0.52	1.50

EFFECT OF PEPTIDES FROM CASEIN EFFECT ON NK PROLIFERATION



Fig. 3a

Patient	Control	Peptides from Casein
1	7.90	10.40
2	8.19	10.46
3	12.82	58.64
4	62.86	50.44
5	5.49	47.76
Mean	19.45	35.54
SD	24.41	23.27

EFFECT OF PEPTIDES FROM CASEIN EFFECT ON T CELL PROLIFERATION



Fig. 3b

T Cells antigens

Patient	Control	Peptides from Casein
1	8.00	25.00
2	1.1	4.3
3	0.1	0.85
4	2.77	3.89
5	1.74	4.34
6	0.84	4.53
7	0	2.55
Mean	2.08	6.49
SD	2.78	8.27

EFFECT OF PEPTIDES FROM CASEIN ON PBSC PROLIFERATION



Fig. 3c

PEPTIDE 0		10 ug/ml		25 ug/ml		100 ug/ml		250 ug/ml		500 ug/ml	
1a	4.3%	*1880	7%	1803	6.2%	2006	9.2%	1761	5.6%	1768	5.6%
2a	4.3%	1762	5.6%	1908	7.7%	1840	6.7%	1805	6.2%	1883	7.4%
3a	4.3%	2003	9.1%	1868	7.1%	1847	6.8%	1671	4.2%	1997	9.1%



Fig. 4

Blood origin	Incubation period (days)	Control	50 (μg/ml)	100 (μg/ml)	300 (μg/ml)	600 (μg/ml)
PBSC	20	1663	3007	1800	4306	3310
PBSC	15	741	1612	784	-	920
BM Normal	21	675	-	660	834	817
BM Auto	21	945	-	916	1537	1284
BM 1	21	1829	4217	4396	9178	1446
BM 2	21	1829	5039	2939	1496	-
CB1	14	1159	1191	1694	3961	3297
CB2	14	3434	-	10882	-	13560



Fig. 5a



Fig. 5b



Fig. 5c

Donor	Days Of Incubation	Factors Added	**Relative Cell No. X 10^4/ml μg Peptides from Casein/ml**				
			0	25	100	250	500
Bone Marow	14	EPO, hIL-3, hSCF, AB serum	41	64	-	67	51
Cord Blood	13	EPO, hIL-3, hSCF, AB serum	27	158	66	50	-

Fig. 6

Synthetic Casein-Derived Peptides

EFFECT OF PEPTIDE LENGTH ON RELATIVE CELL DISTRIBUTION (DIFFERENTIAL COUNT) (%)

Identification	PEPTIDE'S LENGTH	CONC.' (µg)	Mcp	PMN	EARLY MK	LATE MK	TOTAL MK	EARLY RBC	LATE RBC	TOTAL RBC	PLASMA CELLS	DENDRITIC CELLS	EOS BAS	MITOSES	TOTAL
74	2	25	17.8	2.6	3.5	3.7	7.2	15.8	20.4	36.2	8.3	23.0	2.8	4	544
1P	3	25	11.3	2.9	8.8	5.4	14.2	16.5	38.6	55.1	6.7	7.5	2.3	9	521
2P	4	25	6.1	2.3	7.4	9.1	16.5	19.4	51.8	71.2	-	-	0.6	4	700
3P	5	25	12.9	1.8	16.0	16.9	32.9	18.9	23.4	42.3	2.2	7.4	0.5	2	551
4P	6	25	22.0	3.1	21.6	24.6	46.2	5.7	11.5	17.2	0.1	4.5	4.6	4	842
5P	7	25	30.1	9.0	7.8	7.5	15.3	12.9	12.8	25.7	2.4	14.0	3.5	5	744
X	9	25	30.0	6.6	5.6	3.0	8.6	16.4	18.5	34.9	0.5	15.2	4.3	2	762
2a	11	25	8.6	1.6	14.2	28.9	43.1	13.5	26.5	40.0	3.0	3.0	0.6	12	931
2a	11	250	8.4	0.9	19.4	19.8	39.2	12.6	35.0	47.6	2.2	0.5	1.2	11	651
3a	12	25	9.5	1.8	24.1	22.5	46.6	14.0	23.4	37.4	-	3.7	1.0	16	779
D	16	25	41.0	4.5	7.0	7.6	14.6	9.6	20.2	29.8	3.4	-	6.8	7	471
D	16	250	26.6	4.8	11.9	19.4	31.3	4.2	13.1	17.3	12.3	2.4	4.5	6	620
E	17	100	15.4	5.1	12.9	14.5	27.4	20.5	23.6	44.1	4.5	1.4	2.2	7	552
E	17	1250	7.0	2.1	12.7	19.2	31.9	15.2	36.2	51.4	3.2	0.7	3.8	11	759
F	18	25	17.8	4.8	14.5	19.3	33.8	8.6	24.3	32.9	7.2	-	3.4	9	580
F	18	250	9.9	6.1	18.3	19.5	37.8	15.0	27.9	42.9	2.2	0.5	0.6	13	791
G	19	25	19.9	9.7	14.4	17.0	31.4	8.8	15.3	24.1	9.7	-	5.2	5	659
H	20	25	12.8	3.3	17.0	31.2	48.2	15.4	17.6	33.0	1.8	0.6	0.4	11	826
I	21	25	19.2	9.0	11.9	30.0	41.9	7.9	20.9	28.8	1.4	-	-	8	708
J	22	25	15.0	4.5	13.2	14.0	27.2	18.9	28.4	47.3	4.0	0.2	1.8	15	952
K	23	25	28.6	14.9	3.9	6.5	10.4	3.2	-	3.2	6.5	14.3	22.1	1	154
L	24	25	10.4	3.6	18.9	36.8	55.7	10.3	12.2	22.5	4.6	2.2	0.9	14	768
N	26	100	13.8	3.6	13.6	16.4	30.0	12.4	14.2	26.6	1.5	19.8	4.6	14	675
control (without synthetic peptides			17.4	1.6	12.4	10.6	23.0	13.1	44.0	57.1	0.3	0.1	0.2	10	686

Fig. 7

Day After Treatment	2		4		6		9		12		15	
	Control	Peptides from Casein	Control	Peptides from Casein	Control	Peptides from Casein	Control	Peptides from Casein	Control	Peptides from Casein	Control	Peptides from Casein
1	6	9	6	32	55	55	90	205	100	280	500	800
2	10	10	18	34	40	45	135	100	160	280	440	540
3	4	6	14	40	20	85	100	130	140	220	380	800
4	6	6	8	14	35	58	130	125	280	440	600	640
5	12	6	16	18	75	60	70	155	40	340	520	600
6	8	10	18	90	25	45	85	90	320	160	380	640
Mean	*7.67*	*7.83*	*13.33*	*38**	*41.67*	*58**	*101.67*	*134.17*	*173.33*	*286.67*	*470*	*670*
SD	*2.69*	*1.86*	*4.71*	*24.95*	*18.63*	*13.42*	*23.57*	*38.01*	*97.75*	*88.44*	*78.95*	*97.81*

* $p<0.008$



Fig. 8

Day After Treatment	11		13		15	
	Control	Peptides from Casein	Control	Peptides from Casein	Control	Peptides from Casein
1	43	50	75	103	98	110
2	48	54	71	105	99	128
3	68	68	80	110	102	111
4	64	64	104	104	96	103
5	67	67	91	101	104	133
6	63	54	90	90	97	114
7	54	45	104	107	87	104
8		63		104		116
9		61		93		115
10		57		116		112
Mean	*58.14*	*58.3*	*87.86*	*103.3**	*97.57*	*114.6***

* p<0.01 ** p<0.0001



Fig. 9



Fig. 10a



Fig. 10b



Fig. 10c



Fig. 10d

Fig. 10e



Fig. 10f

Peptides from Casein µg/ml	3 days		7 days	
	cpm Counts	Proliferation Index	cpm Counts	Proliferation Index
50	9268	1.18	120954	1.10
100	9940	1.26	112436	1.02
300	8425	1.07	102957	0.93
600	9771	1.24	101987	0.93
1000	8390	1.06	86649	0.79
Control	7862		109560	

Peptides from Casein µg/ml	10 days		14 days	
	cpm Counts	Proliferation Index	cpm Counts	Proliferation Index
50	17695	1.03	22272	1.36
100	19168	1.12	22842	1.40
300	21806	1.28	15318	0.93
600	22826	1.34	17368	1.06
1000	21764	1.28	10034	0.61
Control	17046		16313	

Fig. 11

	Peptides from Casein µg/ml	CEM cells	
		Cell No. ($x10^6$) 15 days	P^{24}Ag ng/ml
3H	50	0.29	16.39
	100	0.55	7.73
	300	0.54	1.61
	600	0.75	0.18
	1000	0.57	0.19
24H	50	0.40	0.24
	100	0.48	4.21
	300	0.56	2.94
	600	0.62	0.18
	1000	0.79	4.03
48H	50	0.37	10.05
	100	0.50	9.16
	300	0.56	3.21
	600	0.70	16.49
	1000	0.84	2.16
Control	IF	0.35	11.42
	UIF	0.42	0.17

Fig. 12

Peptide (3hr pre-treatment)	Conc. μg/ml	CEM cells	
		Cell No. (x10^6) 15 days	P^{24}Ag ng/ml
1P (SEQ ID NO 2)	100	1.29	0.17
	500	2.01	0.14
3P (SEQ ID NO 4)	10	1.17	0.26
	25	1.26	0.18
4P (SEQ ID NO 5)	25	1.26	0.42
	100	1.00	1.4
	250	1.59	0.10
Control	IF	1.06	0.52
	UIF	0.42	0.17

Fig. 13



Fig. 14

Sample*	Group**	Food	TC	HDL	LDL
1	Normal	Normal	91	48	<1
2		Normal	92	56	<1
3	Control	Enriched	375	58	305
4		Enriched	411	51	348
5	B	Enriched	442	52	372
6		Enriched	445	42	386
7	C	Enriched	409	52	341
8		Enriched	411	37	361
9	2a	Enriched	279	36	229
10		Enriched	278	47	213
11	3P	Enriched	312	42	251
12		Enriched	305	43	243

* One blood sample represents blood drawn from 2 mice.
** Each group included 4 mice.

MEAN VALUES

		TC	HDL	LDL
1+2	Normal	91.5	52	<1
3+4	Control	393	54.5	326.5
5+6	B	449.5	47	379
7+8	C	410	44.5	351
9+10	2a	278.5	42	221
11+12	3P	308.5	42.5	247



Fig. 15

Patient	WBC		PLT		RBC		HGB	
	Before	After	Before	After	Before	After	Before	After
1 G.T.	1,200 n	4,100 n+241%	17,000 n	224,000 n+1217%	3.27 n	4.05 n+23%	10.4 n	12.6 n+21%
2 E.C.	5,400 n.	6,300 n+16.6%	204,000 n	259,000 n+26.9%	3.37 n	3.46 n+2.6%	10.8 n	11.0 n+1.8%
3 E.S.	3,400 n	5,100 n+50%	12,700 n	17,900 n+40%	4.49 n	4.71 n+8.4%	12.9 n	13.2 n+2.3%
4 J.R.	4,900 n	6,400 n+30%						
5 D.M.	700 n	4,600 n+557%	47,000 n	151,000 n+221%	2.88 n	3.45 n+19.7%	8.6 n	10.5 n+22%

WBC - White blood cells
PLT - Platelets
RBC - Red blood cells
HGB - Hemoglobin

Fig. 16

X	Y
0	11
1	10
3	10
5	32.5
7	15
8	27.5
12	40
14.25	28
17	35
21	45
26.35	70.3
31.7	74
40	100.7



Fig. 17

X	Y
0	23
1	18.5
2	25
3	16
4	20.8
6	20.8
7	20
8	23.5
9	26
10	19.5
11	23
13	18.5
14	18.5
15	20
17.2	22
20.3	30
24	44
29	75.6
36.5	86.4
41	139.5



Fig. 18

Myeloid Colonies / 1x10^5 MNC plated (CFU-GM)
CFU-GM

Factor added	Colonies per 10^5 MNC Plated
Control + IL-3	52
G-CSF+ IL-3	61
30-4 + IL-3	58
J + IL-3	52
G-CSF+ 30-4 + IL-3	72
G-CSF+ J + IL-3	76

Fig. 19

Myeloid Colonies / 1x10^5 MNC plated (CFU-GM)
CFU-GM

Factor added	Conc.	Colonies per 10^5 MNC Plated	Enhancement of Response to GCSF
G-CSF	75 units/ml	50	0
J + G-CSF	100 µg/ml	77	1.54
	300 µg/ml	60	1.2
β + G-CSF	100 µg/ml	58	1.16
	300 µg/ml	65	1.3

Fig. 20

Percent Megakaryocytes of Total Cells Counted

Factor Added	Conc.	Early MK	Late MK	Total MK
Control		4.4	13.6	18.0
Synthetic Kappa (106-127)(SEQ ID NO: 30)	25µg	6.8	15.0	21.8
Synthetic Beta (193-208)(SEQ ID NO: 28)	25µg	7.5	16.4	23.9
Synthetic Alpha-S1 (1-22)(SEQ ID NO:21)	25µg	12.7	15.5	28.2

Fig. 21

Number of Colonies from Murine Bone Marrow Progenitor Cells (CFU-GEMM)

Factor Added	Days of Incubation	Conc. µg/ml	
		0	25
β (SEQ ID NO: 28)	8	17	38
κ(SEQ ID NO: 30)	8	17	36
β + κ	8	17	62

Fig. 22

Platelet reconstitution

Factor added	Platelet count ($x10^{-3}$) per ml at 10 days
Control	332
J (SEQ ID NO: 21)1mg	445
Control	338
β (SEQ ID NO: 28)1mg	447
Control	370
κ (SEQ ID NO: 30) 1mg	468

Fig. 23

Leukocyte Proliferation (Mean WBC counts)

Factor Added	5 Days	7 Days	10 Days
α-S1(1-23)	5.25×10^4	52.5×10^4	1.80×10^6
κ-casein (106-169)	7.20×10^4	79.0×10^4	1.76×10^6
β-casein(Synthetic) (SEQ ID NO: 28)	17.4×10^4	56.0×10^4	1.90×10^6
α-S1casein(1-22)(Synthetic) (SEQ ID NO: 21)	7.80×10^4	72.0×10^4	1.70×10^6
Control	4.80×10^4	39.0×10^4	1.56×10^6

Fig. 24

Leukocyte Proliferation (Mean WBC counts)

Factor added	WBC ($x 10^{-3}$ per mm^3) at		
	day 4	day 10	day 12
J (αS1 1-22) (SEQ ID NO: 21)	2.3	35.8	35.2
β-casein (193-208) (SEQ ID NO: 28)	4.0	28.0	32.8
J+ β	3.0	31.0	41.0
Saline	2.2	25.2	36.8

Fig. 25

Chimeric Peptides of αS1- and β-casein

αS1-peptide	SEQ ID NO:	β- peptide YQ	SEQ ID NO:	β- peptide YQE
RP	34	RPYQ	35	RPYQE
RPK	36	RPKYQ	37	RPKYQE
RPKH	38	RPKHYQ	39	RPKHYQE
RPKHP	40	RPKHPYQ	41	RPKHPYQE
RPKHPI	42	RPKHPIYQ	43	RPKHPIYQE
RPKHPIK	44	RPKHPIKYQ	45	RPKHPIKYQE
RPKHPIKH	46	RPKHPIKHYQ	47	RPKHPIKHYQE
RPKHPIKHQ	48	RPKHPIKHQYQ	49	RPKHPIKHQYQE
RPKHPIKHQG	50	RPKHPIKHQGYQ	51	RPKHPIKHQGYQE
RPKHPIKHQGL	52	RPKHPIKHQGLYQ	53	RPKHPIKHQGLYQE
RPKHPIKHQGLP	54	RPKHPIKHQGLPYQ	55	RPKHPIKHQGLPYQE
RPKHPIKHQGLPQ	56	RPKHPIKHQGLPQYQ	57	RPKHPIKHQGLPQYQE
RPKHPIKHQGLPQE	58	RPKHPIKHQGLPQEYQ	59	RPKHPIKHQGLPQEYQE
RPKHPIKHQGLPQEV	60	RPKHPIKHQGLPQEVYQ	61	RPKHPIKHQGLPQEVYQE
RPKHPIKHQGLPQEVL	62	RPKHPIKHQGLPQEVLYQ	63	RPKHPIKHQGLPQEVLYQE
RPKHPIKHQGLPQEVLN	64	RPKHPIKHQGLPQEVLNYQ	65	RPKHPIKHQGLPQEVLNYQE
RPKHPIKHQGLPQEVLNE	66	RPKHPIKHQGLPQEVLNEYQ	67	RPKHPIKHQGLPQEVLNEYQE

Fig. 26a

RPKHPIKHQGLPQEVLNEN	68	RPKHPIKHQGLPQEVLNENYQ	69	RPKHPIKHQGLPQEVLNENYQE
RPKHPIKHQGLPQEVLNENL	70	RPKHPIKHQGLPQEVLNENLYQ	71	RPKHPIKHQGLPQEVLNENLYQE
RPKHPIKHQGLPQEVLNENLL	72	RPKHPIKHQGLPQEVLNENLLYQ	73	RPKHPIKHQGLPQEVLNENLLYQE
RPKHPIKHQGLPQEVLNENLLR	74	RPKHPIKHQGLPQEVLNENLLRYQ	75	RPKHPIKHQGLPQEVLNENLLRYQE
RPKHPIKHQGLPQEVLNENLLRF	76	RPKHPIKHQGLPQEVLNENLLRFYQ	77	RPKHPIKHQGLPQEVLNENLLRFYQE
RPKHPIKHQGLPQEVLNENLLRFF	78	RPKHPIKHQGLPQEVLNENLLRFFYQ	79	RPKHPIKHQGLPQEVLNENLLRFFYQE
RPKHPIKHQGLPQEVLNENLLRFFV	80	RPKHPIKHQGLPQEVLNENLLRFFVYQ	81	RPKHPIKHQGLPQEVLNENLLRFFVYQE
RPKHPIKHQGLPQEVLNENLLRFFVA	82	RPKHPIKHQGLPQEVLNENLLRFFVAYQ	83	RPKHPIKHQGLPQEVLNENLLRFFVAYQE
	SEQ ID NO:	YQEP	SEQ ID NO:	YQEPV
RP	84	RPYQEP	85	RPYQEPV
RPK	86	RPKYQEP	87	RPKYQEPV
RPKH	88	RPKHYQEP	89	RPKHYQEPV
RPKHP	90	RPKHPYQEP	91	RPKHPYQEPV
RPKHPI	92	RPKHPIYQEP	93	RPKHPIYQEPV
RPKHPIK	94	RPKHPIKYQEP	95	RPKHPIKYQEPV
RPKHPIKH	96	RPKHPIKHYQEP	97	RPKHPIKHYQEPV
RPKHPIKHQ	98	RPKHPIKHQYQEP	99	RPKHPIKHQYQEPV
RPKHPIKHQG	100	RPKHPIKHQGYQEP	101	RPKHPIKHQGYQEPV
RPKHPIKHQGL	102	RPKHPIKHQGLYQEP	103	RPKHPIKHQGLYQEPV
RPKHPIKHQGLP	104	RPKHPIKHQGLPYQEP	105	RPKHPIKHQGLPYQEPV
RPKHPIKHQGLPQ	106	RPKHPIKHQGLPQYQEP	107	RPKHPIKHQGLPQYQEPV
RPKHPIKHQGLPQE	108	RPKHPIKHQGLPQEYQEP	109	RPKHPIKHQGLPQEYQEPV
RPKHPIKHQGLPQEV	110	RPKHPIKHQGLPQEVYQEP	111	RPKHPIKHQGLPQEVYQEPV
RPKHPIKHQGLPQEVL	112	RPKHPIKHQGLPQEVLYQEP	113	RPKHPIKHQGLPQEVLYQEPV
RPKHPIKHQGLPQEVLN	114	RPKHPIKHQGLPQEVLNYQEP	115	RPKHPIKHQGLPQEVLNYQEPV
RPKHPIKHQGLPQEVLNE	116	RPKHPIKHQGLPQEVLNEYQEP	117	RPKHPIKHQGLPQEVLNEYQEPV
RPKHPIKHQGLPQEVLNEN	118	RPKHPIKHQGLPQEVLNENYQEP	119	RPKHPIKHQGLPQEVLNENYQEPV

Fig. 26b

RPKHPIKHQGLPQEVLNENL	120	RPKHPIKHQGLPQEVLNENLYQEP	121	RPKHPIKHQGLPQEVLNENLYQEPV
RPKHPIKHQGLPQEVLNENLL	122	RPKHPIKHQGLPQEVLNENLLYQEP	123	RPKHPIKHQGLPQEVLNENLLYQEPV
RPKHPIKHQGLPQEVLNENLLR	124	RPKHPIKHQGLPQEVLNENLLRYQEP	125	RPKHPIKHQGLPQEVLNENLLRYQEPV
RPKHPIKHQGLPQEVLNENLLRF	126	RPKHPIKHQGLPQEVLNENLLRFYQEP	127	RPKHPIKHQGLPQEVLNENLLRFYQEPV
RPKHPIKHQGLPQEVLNENLLRFF	128	RPKHPIKHQGLPQEVLNENLLRFFYQEP	129	RPKHPIKHQGLPQEVLNENLLRFFYQEPV
RPKHPIKHQGLPQEVLNENLLRFFV	130	RPKHPIKHQGLPQEVLNENLLRFFVYQEP	131	RPKHPIKHQGLPQEVLNENLLRFFVYQEPV
RPKHPIKHQGLPQEVLNENLLRFFVA	132	RPKHPIKHQGLPQEVLNENLLRFFVAYQEP	133	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPV
	SEQ ID NO:	YQEPVL	SEQ ID NO:	YQEPVLG
RP	134	RPYQEPVL	135	RPYQEPVLG
RPK	136	RPKYQEPVL	137	RPKYQEPVLG
RPKH	138	RPKHYQEPVL	139	RPKHYQEPVLG
RPKHP	140	RPKHPYQEPVL	141	RPKHPYQEPVLG
RPKHPI	142	RPKHPIYQEPVL	143	RPKHPIYQEPVLG
RPKHPIK	144	RPKHPIKYQEPVL	145	RPKHPIKYQEPVLG
RPKHPIKH	146	RPKHPIKHYQEPVL	147	RPKHPIKHYQEPVLG
RPKHPIKHQ	148	RPKHPIKHQYQEPVL	149	RPKHPIKHQYQEPVLG
RPKHPIKHQG	150	RPKHPIKHQGYQEPVL	151	RPKHPIKHQGYQEPVLG
RPKHPIKHQGL	152	RPKHPIKHQGLYQEPVL	153	RPKHPIKHQGLYQEPVLG
RPKHPIKHQGLP	154	RPKHPIKHQGLPYQEPVL	155	RPKHPIKHQGLPYQEPVLG
RPKHPIKHQGLPQ	156	RPKHPIKHQGLPQYQEPVL	157	RPKHPIKHQGLPQYQEPVLG
RPKHPIKHQGLPQE	158	RPKHPIKHQGLPQEYQEPVL	159	RPKHPIKHQGLPQEYQEPVLG
RPKHPIKHQGLPQEV	160	RPKHPIKHQGLPQEVYQEPVL	161	RPKHPIKHQGLPQEVYQEPVLG
RPKHPIKHQGLPQEVL	162	RPKHPIKHQGLPQEVLYQEPVL	163	RPKHPIKHQGLPQEVLYQEPVLG
RPKHPIKHQGLPQEVLN	164	RPKHPIKHQGLPQEVLNYQEPVL	165	RPKHPIKHQGLPQEVLNYQEPVLG
RPKHPIKHQGLPQEVLNE	166	RPKHPIKHQGLPQEVLNEYQEPVL	167	RPKHPIKHQGLPQEVLNEYQEPVLG
RPKHPIKHQGLPQEVLNEN	168	RPKHPIKHQGLPQEVLNENYQEPVL	169	RPKHPIKHQGLPQEVLNENYQEPVLG
RPKHPIKHQGLPQEVLNENL	170	RPKHPIKHQGLPQEVLNENLYQEPVL	171	RPKHPIKHQGLPQEVLNENLYQEPVLG

Fig. 26c

RPKHPIKHQGLPQEVLNENLL	172	RPKHPIKHQGLPQEVLNENLLYQEPVL	173	RPKHPIKHQGLPQEVLNENLLYQEPVLG
RPKHPIKHQGLPQEVLNENLLR	174	RPKHPIKHQGLPQEVLNENLLRYQEPVL	175	RPKHPIKHQGLPQEVLNENLLRYQEPVLG
RPKHPIKHQGLPQEVLNENLLRF	176	RPKHPIKHQGLPQEVLNENLLRFYQEPVL	177	RPKHPIKHQGLPQEVLNENLLRFYQEPVLG
RPKHPIKHQGLPQEVLNENLLRFF	178	RPKHPIKHQGLPQEVLNENLLRFFYQEPVL	179	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLG
RPKHPIKHQGLPQEVLNENLLRFFV	180	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVL	181	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLG
RPKHPIKHQGLPQEVLNENLLRFFVA	182	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVL	183	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLG
	SEQ ID NO:	YQEPVLGP	SEQ ID NO:	YQEPVLGPV
RP	184	RPYQEPVLGP	185	RPYQEPVLGPV
RPK	186	RPKYQEPVLGP	187	RPKYQEPVLGPV
RPKH	188	RPKHYQEPVLGP	189	RPKHYQEPVLGPV
RPKHP	190	RPKHPYQEPVLGP	191	RPKHPYQEPVLGPV
RPKHPI	192	RPKHPIYQEPVLGP	193	RPKHPIYQEPVLGPV
RPKHPIK	194	RPKHPIKYQEPVLGP	195	RPKHPIKYQEPVLGPV
RPKHPIKH	196	RPKHPIKHYQEPVLGP	197	RPKHPIKHYQEPVLGPV
RPKHPIKHQ	198	RPKHPIKHQYQEPVLGP	199	RPKHPIKHQYQEPVLGPV
RPKHPIKHQG	200	RPKHPIKHQGYQEPVLGP	201	RPKHPIKHQGYQEPVLGPV
RPKHPIKHQGL	202	RPKHPIKHQGLYQEPVLGP	203	RPKHPIKHQGLYQEPVLGPV
RPKHPIKHQGLP	204	RPKHPIKHQGLPYQEPVLGP	205	RPKHPIKHQGLPYQEPVLGPV
RPKHPIKHQGLPQ	206	RPKHPIKHQGLPQYQEPVLGP	207	RPKHPIKHQGLPQYQEPVLGPV
RPKHPIKHQGLPQE	208	RPKHPIKHQGLPQEYQEPVLGP	209	RPKHPIKHQGLPQEYQEPVLGPV
RPKHPIKHQGLPQEV	210	RPKHPIKHQGLPQEVYQEPVLGP	211	RPKHPIKHQGLPQEVYQEPVLGPV
RPKHPIKHQGLPQEVL	212	RPKHPIKHQGLPQEVLYQEPVLGP	213	RPKHPIKHQGLPQEVLYQEPVLGPV
RPKHPIKHQGLPQEVLN	214	RPKHPIKHQGLPQEVLNYQEPVLGP	215	RPKHPIKHQGLPQEVLNYQEPVLGPV
RPKHPIKHQGLPQEVLNE	216	RPKHPIKHQGLPQEVLNEYQEPVLGP	217	RPKHPIKHQGLPQEVLNEYQEPVLGPV
RPKHPIKHQGLPQEVLNEN	218	RPKHPIKHQGLPQEVLNENYQEPVLGP	219	RPKHPIKHQGLPQEVLNENYQEPVLGPV
RPKHPIKHQGLPQEVLNENL	220	RPKHPIKHQGLPQEVLNENLYQEPVLGP	221	RPKHPIKHQGLPQEVLNENLYQEPVLGPV
RPKHPIKHQGLPQEVLNENLL	222	RPKHPIKHQGLPQEVLNENLLYQEPVLGP	223	RPKHPIKHQGLPQEVLNENLLYQEPVLGPV

Fig. 26d

RPKHPIKHQGLPQEVLNENLLR	224	RPKHPIKHQGLPQEVLNENLLRYQEPVLGP	225	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPV
RPKHPIKHQGLPQEVLNENLLRF	226	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGP	227	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPV
RPKHPIKHQGLPQEVLNENLLRFF	228	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGP	229	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPV
RPKHPIKHQGLPQEVLNENLLRFFV	230	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGP	231	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPV
RPKHPIKHQGLPQEVLNENLLRFFVA	232	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGP	233	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPV
	SEQ ID NO:	YQEPVLGPVR	SEQ ID NO:	YQEPVLGPVRG
RP	234	RPYQEPVLGPVR	235	RPYQEPVLGPVRG
RPK	236	RPKYQEPVLGPVR	237	RPKYQEPVLGPVRG
RPKH	238	RPKHYQEPVLGPVR	239	RPKHYQEPVLGPVRG
RPKHP	240	RPKHPYQEPVLGPVR	241	RPKHPYQEPVLGPVRG
RPKHPI	242	RPKHPIYQEPVLGPVR	243	RPKHPIYQEPVLGPVRG
RPKHPIK	244	RPKHPIKYQEPVLGPVR	245	RPKHPIKYQEPVLGPVRG
RPKHPIKH	246	RPKHPIKHYQEPVLGPVR	247	RPKHPIKHYQEPVLGPVRG
RPKHPIKHQ	248	RPKHPIKHQYQEPVLGPVR	249	RPKHPIKHQYQEPVLGPVRG
RPKHPIKHQG	250	RPKHPIKHQGYQEPVLGPVR	251	RPKHPIKHQGYQEPVLGPVRG
RPKHPIKHQGL	252	RPKHPIKHQGLYQEPVLGPVR	253	RPKHPIKHQGLYQEPVLGPVRG
RPKHPIKHQGLP	254	RPKHPIKHQGLPYQEPVLGPVR	255	RPKHPIKHQGLPYQEPVLGPVRG
RPKHPIKHQGLPQ	256	RPKHPIKHQGLPQYQEPVLGPVR	257	RPKHPIKHQGLPQYQEPVLGPVRG
RPKHPIKHQGLPQE	258	RPKHPIKHQGLPQEYQEPVLGPVR	259	RPKHPIKHQGLPQEYQEPVLGPVRG
RPKHPIKHQGLPQEV	260	RPKHPIKHQGLPQEVYQEPVLGPVR	261	RPKHPIKHQGLPQEVYQEPVLGPVRG
RPKHPIKHQGLPQEVL	262	RPKHPIKHQGLPQEVLYQEPVLGPVR	263	RPKHPIKHQGLPQEVLYQEPVLGPVRG
RPKHPIKHQGLPQEVLN	264	RPKHPIKHQGLPQEVLNYQEPVLGPVR	265	RPKHPIKHQGLPQEVLNYQEPVLGPVRG
RPKHPIKHQGLPQEVLNE	266	RPKHPIKHQGLPQEVLNEYQEPVLGPVR	267	RPKHPIKHQGLPQEVLNEYQEPVLGPVRG
RPKHPIKHQGLPQEVLNEN	268	RPKHPIKHQGLPQEVLNENYQEPVLGPVR	269	RPKHPIKHQGLPQEVLNENYQEPVLGPVRG
RPKHPIKHQGLPQEVLNENL	270	RPKHPIKHQGLPQEVLNENLYQEPVLGPVR	271	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRG
RPKHPIKHQGLPQEVLNENLL	272	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVR	273	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRG
RPKHPIKHQGLPQEVLNENLLR	274	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPVR	275	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPVRG

Fig. 26e

RPKHPIKHQGLPQEVLNENLLRF	276	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPVR	277	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPVRG
RPKHPIKHQGLPQEVLNENLLRFF	278	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPVR	279	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPVRG
RPKHPIKHQGLPQEVLNENLLRFFV	280	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPVR	281	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPVRG
RPKHPIKHQGLPQEVLNENLLRFFVA	282	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPVR	283	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPVRG
	SEQ ID NO:	YQEPVLGPVRGP	SEQ ID NO:	YQEPVLGPVRGPF
RP	284	RPYQEPVLGPVRGP	285	RPYQEPVLGPVRGPF
RPK	286	RPKYQEPVLGPVRGP	287	RPKYQEPVLGPVRGPF
RPKH	288	RPKHYQEPVLGPVRGP	289	RPKHYQEPVLGPVRGPF
RPKHP	290	RPKHPYQEPVLGPVRGP	291	RPKHPYQEPVLGPVRGPF
RPKHPI	292	RPKHPIYQEPVLGPVRGP	293	RPKHPIYQEPVLGPVRGPF
RPKHPIK	294	RPKHPIKYQEPVLGPVRGP	295	RPKHPIKYQEPVLGPVRGPF
RPKHPIKH	296	RPKHPIKHYQEPVLGPVRGP	297	RPKHPIKHYQEPVLGPVRGPF
RPKHPIKHQ	298	RPKHPIKHQYQEPVLGPVRGP	299	RPKHPIKHQYQEPVLGPVRGPF
RPKHPIKHQG	300	RPKHPIKHQGYQEPVLGPVRGP	301	RPKHPIKHQGYQEPVLGPVRGPF
RPKHPIKHQGL	302	RPKHPIKHQGLYQEPVLGPVRGP	303	RPKHPIKHQGLYQEPVLGPVRGPF
RPKHPIKHQGLP	304	RPKHPIKHQGLPYQEPVLGPVRGP	305	RPKHPIKHQGLPYQEPVLGPVRGPF
RPKHPIKHQGLPQ	306	RPKHPIKHQGLPQYQEPVLGPVRGP	307	RPKHPIKHQGLPQYQEPVLGPVRGPF
RPKHPIKHQGLPQE	308	RPKHPIKHQGLPQEYQEPVLGPVRGP	309	RPKHPIKHQGLPQEYQEPVLGPVRGPF
RPKHPIKHQGLPQEV	310	RPKHPIKHQGLPQEVYQEPVLGPVRGP	311	RPKHPIKHQGLPQEVYQEPVLGPVRGPF
RPKHPIKHQGLPQEVL	312	RPKHPIKHQGLPQEVLYQEPVLGPVRGP	313	RPKHPIKHQGLPQEVLYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLN	314	RPKHPIKHQGLPQEVLNYQEPVLGPVRGP	315	RPKHPIKHQGLPQEVLNYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNE	316	RPKHPIKHQGLPQEVLNEYQEPVLGPVRGP	317	RPKHPIKHQGLPQEVLNEYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNEN	318	RPKHPIKHQGLPQEVLNENYQEPVLGPVRGP	319	RPKHPIKHQGLPQEVLNENYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNENL	320	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRGP	321	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNENLL	322	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRGP	323	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNENLLR	324	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPVRGP	325	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPVRGPF

Fig. 26f

RPKHPIKHQGLPQEVLNENLLRF	326	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPVRGP	327	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNENLLRFF	328	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPVRGP	329	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNENLLRFFV	330	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPVRGP	331	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPVRGPF
RPKHPIKHQGLPQEVLNENLLRFFVA	332	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPVRGP	333	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPVRGPF
	SEQ ID NO:	YQEPVLGPVRGPFP	SEQ ID NO:	YQEPVLGPVRGPFPI
RP	334	RPYQEPVLGPVRGPFP	335	RPYQEPVLGPVRGPFPI
RPK	336	RPKYQEPVLGPVRGPFP	337	RPKYQEPVLGPVRGPFPI
RPKH	338	RPKHYQEPVLGPVRGPFP	339	RPKHYQEPVLGPVRGPFPI
RPKHP	340	RPKHPYQEPVLGPVRGPFP	341	RPKHPYQEPVLGPVRGPFPI
RPKHPI	342	RPKHPIYQEPVLGPVRGPFP	343	RPKHPIYQEPVLGPVRGPFPI
RPKHPIK	344	RPKHPIKYQEPVLGPVRGPFP	345	RPKHPIKYQEPVLGPVRGPFPI
RPKHPIKH	346	RPKHPIKHYQEPVLGPVRGPFP	347	RPKHPIKHYQEPVLGPVRGPFPI
RPKHPIKHQ	348	RPKHPIKHQYQEPVLGPVRGPFP	349	RPKHPIKHQYQEPVLGPVRGPFPI
RPKHPIKHQG	350	RPKHPIKHQGYQEPVLGPVRGPFP	351	RPKHPIKHQGYQEPVLGPVRGPFPI
RPKHPIKHQGL	352	RPKHPIKHQGLYQEPVLGPVRGPFP	353	RPKHPIKHQGLYQEPVLGPVRGPFPI
RPKHPIKHQGLP	354	RPKHPIKHQGLPYQEPVLGPVRGPFP	355	RPKHPIKHQGLPYQEPVLGPVRGPFPI
RPKHPIKHQGLPQ	356	RPKHPIKHQGLPQYQEPVLGPVRGPFP	357	RPKHPIKHQGLPQYQEPVLGPVRGPFPI
RPKHPIKHQGLPQE	358	RPKHPIKHQGLPQEYQEPVLGPVRGPFP	359	RPKHPIKHQGLPQEYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEV	360	RPKHPIKHQGLPQEVYQEPVLGPVRGPFP	361	RPKHPIKHQGLPQEVYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVL	362	RPKHPIKHQGLPQEVLYQEPVLGPVRGPFP	363	RPKHPIKHQGLPQEVLYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLN	364	RPKHPIKHQGLPQEVLNYQEPVLGPVRGPFP	365	RPKHPIKHQGLPQEVLNYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNE	366	RPKHPIKHQGLPQEVLNEYQEPVLGPVRGPFP	367	RPKHPIKHQGLPQEVLNEYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNEN	368	RPKHPIKHQGLPQEVLNENYQEPVLGPVRGPFP	369	RPKHPIKHQGLPQEVLNENYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNENL	370	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRGPFP	371	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNENLL	372	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRGPFP	373	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNENLLR	374	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPVRGPFP	375	RPKHPIKHQGLPQEVLNENLLRYQEPVLGPVRGPFPI

Fig. 26g

RPKHPIKHQGLPQEVLNENLLRF	376	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPVRGPFP	377	RPKHPIKHQGLPQEVLNENLLRFYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNENLLRFF	378	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPVRGPFP	379	RPKHPIKHQGLPQEVLNENLLRFFYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNENLLRFFV	380	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPVRGPFP	381	RPKHPIKHQGLPQEVLNENLLRFFVYQEPVLGPVRGPFPI
RPKHPIKHQGLPQEVLNENLLRFFVA	382	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPVRGPFP	383	RPKHPIKHQGLPQEVLNENLLRFFVAYQEPVLGPVRGPFPI	
	SEQ ID NO:	YQEPVLGPVRGPFPII	SEQ ID NO:	YQEPVLGPVRGPFPIIV
RP	384	RPYQEPVLGPVRGPFPII	385	RPYQEPVLGPVRGPFPIIV
RPK	386	RPKYQEPVLGPVRGPFPII	387	RPKYQEPVLGPVRGPFPIIV
RPKH	388	RPKHYQEPVLGPVRGPFPII	389	RPKHYQEPVLGPVRGPFPIIV
RPKHP	390	RPKHPYQEPVLGPVRGPFPII	391	RPKHPYQEPVLGPVRGPFPIIV
RPKHPI	392	RPKHPIYQEPVLGPVRGPFPII	393	RPKHPIYQEPVLGPVRGPFPIIV
RPKHPIK	394	RPKHPIKYQEPVLGPVRGPFPII	395	RPKHPIKYQEPVLGPVRGPFPIIV
RPKHPIKH	396	RPKHPIKHYQEPVLGPVRGPFPII	397	RPKHPIKHYQEPVLGPVRGPFPIIV
RPKHPIKHQ	398	RPKHPIKHQYQEPVLGPVRGPFPII	399	RPKHPIKHQYQEPVLGPVRGPFPIIV
RPKHPIKHQG	400	RPKHPIKHQGYQEPVLGPVRGPFPII	401	RPKHPIKHQGYQEPVLGPVRGPFPIIV
RPKHPIKHQGL	402	RPKHPIKHQGLYQEPVLGPVRGPFPII	403	RPKHPIKHQGLYQEPVLGPVRGPFPIIV
RPKHPIKHQGLP	404	RPKHPIKHQGLPYQEPVLGPVRGPFPII	405	RPKHPIKHQGLPYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQ	406	RPKHPIKHQGLPQYQEPVLGPVRGPFPII	407	RPKHPIKHQGLPQYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQE	408	RPKHPIKHQGLPQEYQEPVLGPVRGPFPII	409	RPKHPIKHQGLPQEYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEV	410	RPKHPIKHQGLPQEVYQEPVLGPVRGPFPII	411	RPKHPIKHQGLPQEVYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEVL	412	RPKHPIKHQGLPQEVLYQEPVLGPVRGPFPII	413	RPKHPIKHQGLPQEVLYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEVLN	414	RPKHPIKHQGLPQEVLNYQEPVLGPVRGPFPII	415	RPKHPIKHQGLPQEVLNYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEVLNE	416	RPKHPIKHQGLPQEVLNEYQEPVLGPVRGPFPII	417	RPKHPIKHQGLPQEVLNEYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEVLNEN	418	RPKHPIKHQGLPQEVLNENYQEPVLGPVRGPFPII	419	RPKHPIKHQGLPQEVLNENYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEVLNENL	420	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRGPFPII	421	RPKHPIKHQGLPQEVLNENLYQEPVLGPVRGPFPIIV
RPKHPIKHQGLPQEVLNENLL	422	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRGPFPII	423	RPKHPIKHQGLPQEVLNENLLYQEPVLGPVRGPFPIIV

Fig. 26h

RPKHPIKHQGLPQEVL NENLLR	424	RPKHPIKHQGLPQEVLNENLL RYQEPVLGPVRGPFPII	425	RPKHPIKHQGLPQEVLNE NLLRYQEPVLGPVRGPFP IIV
RPKHPIKHQGLPQEVL NENLLRF	426	RPKHPIKHQGLPQEVLNENLL RFYQEPVLGPVRGPFPII	427	RPKHPIKHQGLPQEVLNE NLLRFYQEPVLGPVRGPF PIIV
RPKHPIKHQGLPQEVL NENLLRFF	428	RPKHPIKHQGLPQEVLNENLL RFFYQEPVLGPVRGPFPII	429	RPKHPIKHQGLPQEVLNE NLLRFFYQEPVLGPVRGP FPIIV
RPKHPIKHQGLPQEVL NENLLRFFV	430	RPKHPIKHQGLPQEVLNENLL RFFVYQEPVLGPVRGPFPII	431	RPKHPIKHQGLPQEVLNE NLLRFFVYQEPVLGPVRG PFPIIV
RPKHPIKHQGLPQEVL NENLLRFFVA	432	RPKHPIKHQGLPQEVLNENLL RFFVAYQEPVLGPVRGPFPII	433	RPKHPIKHQGLPQEVLNE NLLRFFVAYQEPVLGPVR GPFPIIV

Fig. 26i